Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of melanoma recurrence or death by 42% and the risk of cancer spreading or death by 38% compared to Keytruda alone. These promising results, to be presented at a major oncology conference, highlight the vaccine's potential as a breakthrough treatment and a key new product for Moderna beyond its existing vaccines. The stock has surged over 530% this year amid high investor expectations for this therapy's future impact.
Moderna's shares dropped sharply by 23.65% on Pluang, trading at USD 187.67 as of Oct 23, 2026 01:41 WIB, reflecting strong sell pressure with 57% of orders to sell. Merck's stock also declined by 1.25%, priced at USD 148.05, with a majority of 63% sell orders on Pluang at the same time.
Moderna's stock fell sharply by 25% following an unauthorized leak of Phase 3 data for its experimental cancer vaccine developed with Merck. The data was expected to be officially presented at a medical conference this weekend. Merck's shares also de...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
Moderna, known for its mRNA COVID-19 vaccine, is set to reveal full Phase 3 data for its experimental cancer vaccine targeting melanoma. The results, expected this weekend, could mark a breakthrough in cancer treatment using customized mRNA technolog...
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
